LAG-3 con­tin­ues gen­er­at­ing heavy buzz as Aus­trali­a's Im­mutep locks down new funds

An Aus­tralian biotech look­ing to make its mark on the LAG-3 space has pulled in a new round of fund­ing it hopes can kick­start a swath of new clin­i­cal tri­als.

Im­mutep se­cured rough­ly $45 mil­lion in what it’s call­ing a “two-tranche in­sti­tu­tion­al place­ment,” the com­pa­ny an­nounced Mon­day, get­ting some cash from both Aus­tralian in­vestors and in­ter­na­tion­al stake­hold­ers. As part of the raise, Im­mutep will launch four new stud­ies for its lead LAG-3 com­pound efti­lag­i­mod al­pha, in­clud­ing two in metasta­t­ic breast can­cer and non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER